Jean-yves -. Blay-Yves

Lyon, France

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 71 publications

The ethical obligation to use positive trial results.

The ethical obligation to use positive trial results.

Journal: Annals of oncology : official journal of the European Society for Medical Oncology

Published: June 20, 2026

Twenty-five years survival of primary central nervous system lymphomas treated with the C5R regimen.

Twenty-five years survival of primary central nervous system lymphomas treated with the C5R regimen.

Journal: European journal of cancer (Oxford, England : 1990)

Published: June 17, 2026

Molecular profiling and access to treatment for rare cancers in Europe.

Molecular profiling and access to treatment for rare cancers in Europe.

Journal: Nature communications

Published: January 22, 2026

COVID-19 vaccination before immune checkpoint inhibitor initiation and the overall survival of patients with advanced cancer: A cohort study.

COVID-19 vaccination before immune checkpoint inhibitor initiation and the overall survival of patients with advanced cancer: A cohort study.

Journal: European journal of cancer (Oxford, England : 1990)

Published: December 19, 2025

Pimicotinib: a new agent for an orphan disease.

Pimicotinib: a new agent for an orphan disease.

Journal: Lancet (London, England)

Published: December 11, 2025

The Goldilocks paradox: when partial oncoprotein inhibition fuels metastasis in Ewing sarcoma.

The Goldilocks paradox: when partial oncoprotein inhibition fuels metastasis in Ewing sarcoma.

Journal: EMBO molecular medicine

Published: December 03, 2025

Mutation type, tyrosine kinase function in normal cell and tyrosine kinase inhibitor activity in cancers.

Mutation type, tyrosine kinase function in normal cell and tyrosine kinase inhibitor activity in cancers.

Journal: Scientific reports

Published: November 05, 2025

Overcoming the barriers to treatment of rare cancer patients in the era of precision oncology: A call to action.

Overcoming the barriers to treatment of rare cancer patients in the era of precision oncology: A call to action.

Journal: Cancer treatment reviews

Published: June 10, 2025

Twenty-year survival of advanced gastrointestinal stromal tumours treated with imatinib: exploratory long-term follow-up of the BFR14 trial.

Twenty-year survival of advanced gastrointestinal stromal tumours treated with imatinib: exploratory long-term follow-up of the BFR14 trial.

Journal: Annals of oncology : official journal of the European Society for Medical Oncology

Published: April 05, 2025

Radiation-associated angiosarcoma of the breast: consider chemotherapy.

Radiation-associated angiosarcoma of the breast: consider chemotherapy.

Journal: European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology

Published: February 20, 2025

Six-year duration of adjuvant imatinib in high-risk GIST: more to come.

Six-year duration of adjuvant imatinib in high-risk GIST: more to come.

Journal: Annals of oncology : official journal of the European Society for Medical Oncology

Published: November 23, 2024

Omitting study limitations might have implications for the patients - Authors' reply.

Omitting study limitations might have implications for the patients - Authors' reply.

Journal: The Lancet. Oncology

Published: October 02, 2024

Showing 1-12 of 71

Last Updated: 09/26/2026